National trends in osteoporosis visits and osteoporosis treatment, 1988-2003

Archives of Internal Medicine

Volumn 164, Issue 14, 2004, Pages 1525-1530

  Stafford, Randall S ^a   Drieling, Rebecca L ^a   Hersh, Adam L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; ESTROGEN; ETIDRONIC ACID; NEW DRUG; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; AMBULATORY CARE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRACTURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOPOROSIS; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL;

ADULT; AGED; CALCIUM; DIPHOSPHONATES; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; OSTEOPOROSIS; PRESCRIPTIONS, DRUG; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UNITED STATES;

EID: 3242808066     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.14.1525     Document Type: Article

References (42)

1. Ray NF, Chan JK, Thamer M, Melton JL. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Treatment. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
3. Geusens P, Hochberg M, van der Voort D, et al. Performance of risk indices for identifying low bone density in postmenopausal women. Mayo Clin Proc. 2002;77:629-637.
4. Siris E, Miller P, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA. 2001;286:2815-2822.
5. Chesnut CH III. Osteoporosis, an underdiagnosed disease. JAMA. 2001;286:2865-2866.
6. Cuddihy M, Amadio P, Melton LJ III. Patient barriers to osteoporosis interventions after fracture. Mayo Clin Proc. 2002;77:875-876.
7. Lee E, Zuckerman IH, Weiss SR. Patterns of pharmacotherapy and counseling for osteoporosis management in visits to US ambulatory care physicians by women. Arch Intern Med. 2002;162:2362-2366.
8. US Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526-528.
9. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. 2002;359:2018-2026.
10. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C, for the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group, IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-578.
11. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study): a randomized controlled trial. JAMA. 1996;276:1397-1403.
12. Ravn P, Bidstrup M, Wasnich R, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial. Ann Intern Med. 1999;131:935-942.
13. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1996;276:1389-1396.
14. Miller P, Watts N, Licata A, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med. 1997;103:468-478.
15. Liberman U, Weiss S, Broll J, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
16. Hulley S, Furberg C, Barrett-Connor E, et al, for the HERS Research Group, Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:58-66.
17. Harris S, Watts N, Genant H, et al, for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
18. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
19. Ensrud K, Black D, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med. 1997;157:2617-2624.
20. Rossouw J, Anderson G, Prentice R, et al, for the Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
21. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997;350:1047-1059.
22. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001;285:1415-1418.
23. Cummings S, Black D, Thompson D, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
24. Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 2001;27:197-214.
25. Gehlbach-SH, Fournier M, Bigelow C. Recognition of osteoporosis by primary care physicians. Am J Public Health. 2002;92:271-273.
26. US Census Bureau, Population Division. Resident Population Estimates of the United States by Age and Sex: April 1, 1990 to July 1, 1999, with Short-Term Projection to November 1, 2000. Available at: http://eire.census.gov/popest /archives/national/nation2/intfile2-1.txt. Accessed February 26, 2003.
27. US Census Bureau, Population Division. Projections of the Total Resident Population by 5-year Age Groups, and Sex with Special Age Categories: Middle Series, 2001 to 2005. Available at: http://www.census.gov/population/projections /nation/summary/np-t3-b.txt. Accessed April 21, 2004.
28. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ. 2002;324:886-891.
29. Harrington J, Broy S, Derosa A, Licata A, Shewmon D. Hip fracture patients are not treated for osteoporosis: a call to action. Arthritis Rheum. 2002;47:651-654.
30. Barrett-Connor E, Grady D, Sashegy IA, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002;287:847-857.
31. Riggs B, Hartmann L, Lynn C. Drug therapy: selective estrogen-receptor modulators: mechanisms of action and application to clinical practice. N Engl J Med. 2003;348:618-629.
32. Wilkes M, Bell R, Kravitz R. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff (Millwood). 2000;19:110-128.
33. Chew L, O'Young T, Hazlet T, Bradley KA, Maynard C, Lessler DS. A physician survey of the effect of drug sample availability on physicians' behavior. J Gen Intern Med. 2000;15:478-483.
34. IMS-Health. Total Promotion Reports 1998: Report TPR-2. Plymouth Meeting, Pa: IMS-Health; 1999.
35. Madhav R, Brooks P, Powles D. Osteoporosis screening in a fracture clinic: simple and successful [abstract]. J Bone Joint Surg Br. 1999;81 (B, suppl 3):296.
36. Miller P, Siris E, Barrett-Connor E, et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res. 2002;17:2222-2230.
37. Cummings S, Bates D, Black D. Clinical use of bone densitometry. JAMA. 2002;288:1889-1897.
38. Kolata G. Menopause without pills: rethinking hot flashes. New York Times. November 10, 2002;§1:1.
39. Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal estrogen therapy: annual trends and response to recent evidence, 1995-2002. JAMA. 2004;291:47-53.
40. Probst J, Moore C, Baxley E, Shinogle J. Osteoporosis recognition: correcting Gehlbach et al. Am J Public Health. 2002;92:1885.
41. Hensrud D, Engle D, Scheitel S. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc. 1999;74:443-447.
42. Yang J, Tomlinson G, Naglie G. Medication lists for elderly patients: clinic-derived versus in-home inspection and interview. J Gen Intern Med. 2001;16:112-115.